148 related articles for article (PubMed ID: 34786489)
1. Hydroxyurea usage awareness among patients with sickle-cell disease in Saudi Arabia.
Alsalman M; Alkhalifa H; Alkhalifa A; Alsubie M; AlMurayhil N; Althafar A; Albarqi M; Alnaim A; Khan AS
Health Sci Rep; 2021 Dec; 4(4):e437. PubMed ID: 34786489
[TBL] [Abstract][Full Text] [Related]
2. Adherence to Hydroxyurea and Patients' Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study.
Madkhali MA; Abusageah F; Hakami F; Zogel B; Hakami KM; Alfaifi S; Alhazmi E; Zaalah S; Trabi S; Alhazmi AH; Mohrag M; Malhan H
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256385
[No Abstract] [Full Text] [Related]
3. Impact of Hydroxyurea Therapy in Reducing Pain Crises, Hospital Admissions, and Length of Stay Among Sickle Cell Patients in the Eastern Region of Saudi Arabia.
Albohassan H; Ammen M; Alomran AA; Bu Shehab H; Al Sakkak H; Al Bohassan A
Cureus; 2022 Nov; 14(11):e31527. PubMed ID: 36540486
[TBL] [Abstract][Full Text] [Related]
4. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE
Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480
[TBL] [Abstract][Full Text] [Related]
5. Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study.
Hankins JS; Shah N; DiMartino L; Brambilla D; Fernandez ME; Gibson RW; Gordeuk VR; Lottenberg R; Kutlar A; Melvin C; Simon J; Wun T; Treadwell M; Calhoun C; Baumann A; Potter MB; Klesges L; Bosworth H;
JMIR Res Protoc; 2020 Jul; 9(7):e16319. PubMed ID: 32442144
[TBL] [Abstract][Full Text] [Related]
6. The role of hydroxyurea in decreasing the occurrence of vasso-occulusive crisis in pediatric patients with sickle cell disease at King Saud Medical City in Riyadh, Saudi Arabia.
Azmet FR; Al-Kasim F; Alashram WM; Siddique K
Saudi Med J; 2020 Jan; 41(1):46-52. PubMed ID: 31915794
[TBL] [Abstract][Full Text] [Related]
7. Patterns of prescribing hydroxyurea for sickle cell disease patients from a central hospital, Saudi Arabia.
Elghazaly AA; Aljatham AA; Khan AM; Elneil RM; Jafar SZS; Elwishy SA; Ahmed OE; Bughnah AM; Ibrahim MH
Hematol Rep; 2019 Feb; 11(1):7860. PubMed ID: 30915204
[TBL] [Abstract][Full Text] [Related]
8. Pharmacy hydroxyurea education materials for patients with sickle cell disease: An environmental scan and assessment of accuracy.
Cervi A; Diamantouros A; Azzam M; Lane SJ; Sapru H; Verhovsek M
Pediatr Blood Cancer; 2020 May; 67(5):e28179. PubMed ID: 31965703
[TBL] [Abstract][Full Text] [Related]
9. Awareness and Acceptance of Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Jazan Province, Saudi Arabia.
Hurissi E; Hakami A; Homadi J; Kariri F; Abu-Jabir E; Alamer R; Mobarki R; Jaly AA; Alamer E; Alhazmi AH
Cureus; 2022 Jan; 14(1):e21013. PubMed ID: 35154985
[TBL] [Abstract][Full Text] [Related]
10. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease.
Haywood C; Beach MC; Bediako S; Carroll CP; Lattimer L; Jarrett D; Lanzkron S
Am J Hematol; 2011 Jan; 86(1):85-7. PubMed ID: 21117058
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea for the treatment of sickle cell disease.
Segal JB; Strouse JJ; Beach MC; Haywood C; Witkop C; Park H; Wilson RF; Bass EB; Lanzkron S
Evid Rep Technol Assess (Full Rep); 2008 Mar; (165):1-95. PubMed ID: 18457478
[TBL] [Abstract][Full Text] [Related]
12. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Stroke in Individuals with Sickle Cell Disease Pre- and during Hydroxyurea Uses: A Descriptive Cross-Sectional Study in Tanzania.
Moshi BN; Philipo EG; Kileo NF; Matobo J; Yondu E; Ikunda D; Kandonga D; Luhulla KM; Kilonzi M
Adv Hematol; 2024; 2024():7950925. PubMed ID: 38533292
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?
Creary SE; Chisolm DJ; Koch TL; Zigmont VA; Lu B; O'Brien SH
Pediatr Blood Cancer; 2016 May; 63(5):844-7. PubMed ID: 26797936
[TBL] [Abstract][Full Text] [Related]
15. Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy.
Thomas R; Dulman R; Lewis A; Notarangelo B; Yang E
Pediatr Blood Cancer; 2019 Sep; 66(9):e27816. PubMed ID: 31157521
[TBL] [Abstract][Full Text] [Related]
16. The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease.
Jabour SM; Beachy S; Coburn S; Lanzkron S; Eakin MN
J Racial Ethn Health Disparities; 2019 Dec; 6(6):1233-1243. PubMed ID: 31410784
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea: Pattern of Use, Patient Adherence, and Safety Profile in Patients with Sickle Cell Disease in Oman.
Jose J; Elsadek RA; Jimmy B; George P
Oman Med J; 2019 Jul; 34(4):327-335. PubMed ID: 31360322
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.
Zumberg MS; Reddy S; Boyette RL; Schwartz RJ; Konrad TR; Lottenberg R
Am J Hematol; 2005 Jun; 79(2):107-13. PubMed ID: 15929107
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.
Creary S; Zickmund S; Ross D; Krishnamurti L; Bogen DL
BMC Res Notes; 2015 Aug; 8():372. PubMed ID: 26303306
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey.
Colombatti R; Palazzi G; Masera N; Notarangelo LD; Bonetti E; Samperi P; Barone A; Perrotta S; Facchini E; Miano M; Del Vecchio GC; Guerzoni ME; Corti P; Menzato F; Cesaro S; Casale M; Rigano P; Forni GL; Russo G; Sainati L;
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28868627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
